

DIFFERENT WAYS TO OVERCOME CHALLENGES – OUR RESPONSES

2^d International workshop

Joint Action on HIV and Co-Infection Prevention and Harm Reduction HA-REACT

24 May 2018, Utrecht, Netherlands

NBC Congress Centrum, Blokhoeve 1, 438 LC Nieuwegein, Netherlands

Room №15



Aljona Kurbatova, head of the Infectious Diseases and Drug Abuse Prevention Center at the National Institute for Health Development

She is a sociologist by education and started working in the public health field in 1998. She has participated in elaboration of different public health strategies and serves on the National HIV Prevention Committee and Governmental Committee on Prevention of Drug Abuse. In her current position she is responsible for development, coordination and financing of health and social services in the field of drug addiction, HIV and tuberculosis prevention, as well as implementation of national and international cooperation projects.



Barbara Janíková, Czech National Monitoring Centre for Drugs and Addiction

In the research field, she is responsible for data of drug-related infectious diseases and drug treatment demand. In addition, she is responsible for cooperation with service providers (harm reduction and treatment facilities) regarding data collection and analysis. Her background is work in low threshold facilities with people who use drugs.



Dovilė Mačiulytė, Republican Centre for Addictive Disorders, Lithuania

Dovile is currently working as an acting head of the Methodological Guidance and Monitoring Department at the Republican Centre for Addictive Disorders in Vilnius, Lithuania. She has an MSc of Public Health from London School of Hygiene and Tropical Medicine.



Geoff McCombe, University College Dublin School of Medicine

He is a research fellow at University College Dublin School of Medicine. His research interests lie at the boundary of social psychology and primary care research. To date his research has looked at how inter-group processes influence the lived experience of socially marginalized groups and understanding how group-based processes and psychosocial interventions influence health outcomes. Since July 2016 he has been working on a large scale European Horizon 2020 funded project (Hepcare Europe) focusing on providing an integrated care model for hepatitis C virus treatment involving partnership between primary and secondary care. Areas of interest include: Primary care research, substance use, the prevention and treatment of blood borne virus infections, social psychology, social identity, social inequality.



Jamie Wilkinson, MPH, MSc, MPharm, Dip HE, FRSPH, MRPharmS, PFPH

Mr Wilkinson commenced his role as Pharmaceuticals and Professional Affairs Adviser of the PGEU in January 2014 before becoming Director of Professional Affairs in April 2015. The Pharmaceutical Group of the European Union (PGEU) is the European Association representing community pharmacists in 32 European countries.

A pharmacist by training, he has practice experience in the community pharmacy sector and academia in the UK, in addition to experience in health policy, professional affairs and advocacy. He was educated at the Universities of Kingston & St Georges London with an MPharm, Master of Pharmacy, an MSc in Social Research Methods from the University of Sussex and an MPH, Master of Public Health from the University of Sheffield. He is a Member of the Royal Pharmaceutical Society UK, a Fellow of the Royal Society for Public Health UK and a Practitioner Member of the Faculty of Public Health UK.



Lars Peters, CHIP, Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark

He is a researcher at the Centre of Excellence for Health, Immunity and Infections (CHIP) in Copenhagen, where he is responsible for research activities in chronic hepatitis B and C including patients co-infected with HIV. He is co-chair of the hepatitis group of the EuroSIDA cohort study, and co-author of the European AIDS Clinical Society (EACS) guidelines for management of HIV/viral hepatitis co-infection and the WHO European Region guidelines for management of HIV/HBV co-infection.



Kristel Kivimets Kristel Kivimets, MSc, expert of the **Infectious Diseases and Drug Abuse Prevention Center at the National Institute for Health Development, PhD student**

She has 14 years of extensive experience in prison system. In her current position she is responsible for the implementation of the European Commission project "Joint Action on HIV and Co-Infection Prevention and Harm Reduction" (HA-REACT). In addition, she is responsible for developing and implementing harm reduction services in Estonia.



Mart Kalvet is a board member at the **Estonian Association of People Who Use Psychotropic Substances LUNEST and the Estonian Medical Cannabis Association**

Occasionally works as a volunteer at the Estonian Network of People Living With HIV. As a harm reduction enthusiast, activist and freelance journalist, he has been arguing for drug law reform, decriminalization and market control, as well as drug user rights and evidence-based drug policies for over a decade. Mart will be coordinating an upcoming pilot program of law enforcement assisted drug user diversion conducted jointly by the Health Development Institute and the police.



Otilia Mardh, European Centre for Disease Prevention and Control, Sweden

Otilia Mardh, MD, MSc is a medical epidemiologist working for ECDC since 2011 where she is attached to the ECDC HIV/AIDS, STI and viral hepatitis programme and Epidemic intelligence and response section. Among other activities, she co-authored the joint ECDC/EMCDDA risk assessment on HIV among PWID in Europe 2012 and the related later publications and is now involved in the ECDC/EMCDDA stakeholder survey on the PWID guidance evaluation.



Tereza Černikova Czech National Monitoring Centre for **Drugs and Addiction**

She is responsible for the implementation of the European Commission project "Joint Action on HIV and Co-Infection Prevention and Harm Reduction" (HA-REACT). Her next focus is on the area of prevention. She graduated from the First Faculty of Medicine at Charles University with a Masters's degree in Addictology in 2018.